MoonLake Immunotherapeutics
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
MLTX$12.62+9.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, 2024 (Unaudited) | December 31, 2023 | |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $375,656,291 | $451,169,337 |
| Short-term marketable debt securities | 118,268,400 | 59,838,900 |
| Other receivables | 2,407,062 | 1,056,862 |
| Prepaid expenses - current | 15,984,425 | 2,102,203 |
| Total current assets | 512,316,178 | 514,167,302 |
| Non-current assets | ||
| Operating lease right-of-use assets | 3,251,197 | 3,628,480 |
| Property and equipment, net | 581,378 | 320,865 |
| Prepaid expenses - non-current | 2,064,575 | 8,423,468 |
| Total non-current assets | 5,897,150 | 12,372,813 |
| Total assets | $518,213,328 | $526,540,115 |
| Current liabilities | ||
| Trade and other payables | $10,710,603 | $1,837,684 |
| Short-term portion of operating lease liabilities | 1,444,893 | 1,197,876 |
| Accrued expenses and other current liabilities | 7,925,524 | 6,930,120 |
| Total current liabilities | 20,081,020 | 9,965,680 |
| Non-current liabilities | ||
| Long-term portion of operating lease liabilities | 1,935,709 | 2,499,990 |
| Pension liability | 694,959 | 583,426 |
| Total non-current liabilities | 2,630,668 | 3,083,416 |
| Total liabilities | 22,711,688 | 13,049,096 |
| Commitments and contingencies (Note 15) | ||
| Equity | ||
| Class A Ordinary Shares: $0.0001 par value; 500,000,000 shares authorized; 63,046,025 shares issued and outstanding as of September 30, 2024; 60,466,453 shares issued and outstanding as of December 31, 2023 | 6,305 | 6,047 |
| Class C Ordinary Shares: $0.0001 par value; 100,000,000 shares authorized; 841,269 shares issued and outstanding as of September 30, 2024; 2,505,476 shares issued and outstanding as of December 31, 2023 | 84 | 251 |
| Additional paid-in capital | 675,343,443 | 609,969,236 |
| Accumulated deficit | (189,988,477) | (116,657,472) |
| Accumulated other comprehensive income | 2,833,970 | 2,357,621 |
| Total shareholders’ equity | 488,195,325 | 495,675,683 |
| Noncontrolling interests | 7,306,315 | 17,815,336 |
| Total equity | 495,501,640 | 513,491,019 |
| Total liabilities and equity | $518,213,328 | $526,540,115 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.